 The Oncology Report | Re-treatment strategy challenges maintenance therapy for rituximab use in low ... HemOncToday SAN DIEGO — Patients with low tumor burden follicular lymphoma who received a maintenance dose of rituximab every 3 months did not have a longer time to treatment failure than patients being treated with rituximab at progression, according to findings ... Observation Suffices After Rituximab in Low-Burden Follicular Lymphoma RESORT Study: Rituximab Retreatment Produces Outcomes Comparable to ... |
